Clinical Significance of Subclinical Myocardial Involvement in Recovered COVID-19 Patients Using Cardiovascular Magnetic Resonance
Key facts
- Who runs it
- The University of Hong Kong
- Where
- Hong Kong1 site in 1 countryChoose a country to see its sites
- Trial code
- Status
- Completed
- People taking part
- 162 people enrolled
- Started
- 4 Oct 2021
- Ended
- 8 Aug 2024
- Type of study
- Interventional, 4 groupsOne group gets an existing treatment, for comparison.
- Treatments tested
- Cardiac Magnetic Resonance, Blood Tests
- Record updated
- 11 May 2025
Who can take part
- Sex
- Women and men
- Healthy volunteers
- Can take part
The registry criteria, word for word
Show all 11 criteriaShow less
Who can take part
- Recovered COVID-19 patients; Definition of recovered COVID-19 patient:
- COVID-19 diagnosis = established by a positive reverse transcription polymerase chain reaction (RT-PCR) for severe acute respiratory syndrome coronavirus-2 [SARS-CoV2] and recovered from COVID-19
- Recovery = based on two criteria: (1) two negative nasopharyngeal swab RT-PCR results >24 hours apart and (2) absence of fever and improvement in respiratory symptoms; Recovered non-COVID-19 patients with viral respiratory infections confirmed with viral polymerase chain reaction testing AND with a confirmed negative COVID-19 RT-PCR test; Age and gender matched controls with no cardiac risk factors, not on cardiac medications, no history of myocardial infarction, heart failure or myocarditis, negative COVID-19 RT-PCR test and negative COVID-19 antibodies test; Vaccination controls who planning to receive a 2-dose COVID-19 vaccine, with no history of myocardial infarction, heart failure or myocarditis AND with a confirmed negative COVID-19 RT-PCR test
Who cannot take part
- Previous myocardial infarction or myocarditis unrelated to COVID-19 infection
- History of heart failure unrelated to COVID-19 infection
- Presence of pacemakers or implantable cardiac defibrillators
- Limited life expectancy <1 year, for example due to pulmonary disease, cancer or significant hepatic failure
- Renal impairment with eGFR <45ml/min/1.73m2
- Any contraindication for CMR testing
- Refusal or inability to sign an informed consent
- Potential for non-compliance towards the requirements in the trial protocol (especially the medical treatment) or follow-up visits
Where is this trial?
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
Introduction:
Read full original descriptionShow less
Coronavirus disease 2019 (COVID-19) remains a major health issue resulting in >800,000 deaths as of 30th August 2020. A concerning discovery of COVID-19 is the involvement of the myocardium. Several case studies including one from our group (recent study publication in JACC Cardiovascular Imaging led by the principal investigator of this grant application) have demonstrated subclinical myocardial inflammation in patients using cardiac magnetic resonance imaging (CMR) who have recovered from COVID-19. Furthermore at a cellular level, a recent autopsy study indicated that the severe acute respiratory syndrome coronavirus-2 is present in the myocardial tissue. The study further described invasion and viral progeny occurring in the myocardial interstitial cells and as such is a concerning development with the longer-term implications being unknown. These concerns have been noticed by the cardiology and non-cardiology medical community, with some expressing concerns of a new cause for cardiomyopathy and heart failure secondary to COVID-195. Therefore, it is critical that further studies are conducted to determine the longer-term outcome for patients.
The 4 groups in the trial
- Recovered COVID-19 patientsExisting treatment, for comparison
Recovered COVID-19 Patients will undergo three CMR examinations. The scans will take place at (i) within 2 weeks of confirmed recovery, (ii) 3 months after recovery and (iii) 1 year after recovery. At time of CMR examinations, patients will have blood tests.
Treatment: Cardiac Magnetic Resonance, Blood Tests
- non-COVID-19 patients with viral respiratory infectionsTreatment being tested
non-COVID-19 Patients will undergo three CMR examinations. The scans will take place at (i) within 2 weeks of confirmed recovery, (ii) 3 months after recovery and (iii) 1 year after recovery. At time of CMR examinations, patients will have blood tests.
Treatment: Cardiac Magnetic Resonance, Blood Tests
- Volunteers as age and gender matched controls.Treatment being tested
Volunteer controls will undergo one CMR examination. At time of CMR examinations, patients will have blood tests.
Treatment: Cardiac Magnetic Resonance, Blood Tests
- Volunteers who planning to receive a 2-dose COVID-19 vaccine as vaccination controlsTreatment being tested
Vaccination controls will undergo two CMR examinations. The scans will take place (i) within 2 weeks before received 1st dose of COVID-19 vaccine and (ii) within 2 weeks (preferably 5-7 days) after receiving the 2nd dose of COVID-19 vaccine. At time of CMR examinations, patients will have blood tests.
Treatment: Cardiac Magnetic Resonance, Blood Tests
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Publications
- Post-COVID-19 vaccination myocarditis: a prospective cohort study pre and post vaccination using cardiovascular magnetic resonance.Journal of cardiovascular magnetic resonance : official journal of the Society for Cardiovascular Magnetic Resonance, 2023
- Record updated
- 11 May 2025